These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33208570)

  • 21. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
    Li N; Chen R; Liu K
    Clin Drug Investig; 2020 Nov; 40(11):991-1000. PubMed ID: 32725362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intermittently scanned continuous glucose monitoring in adult type 1 diabetes patients with suboptimal glycaemic control: A multi-centre randomized controlled trial.
    Yan J; Zhou Y; Zheng X; Zheng M; Lu J; Luo S; Yang D; Deng H; Xu W; Bi Y; Bao W; Weng J
    Diabetes Metab Res Rev; 2023 May; 39(4):e3614. PubMed ID: 36670050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
    Hayashi A; Takano K; Kawai S; Shichiri M
    Endocr J; 2016; 63(2):187-91. PubMed ID: 26549210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia.
    Davis TME; Dwyer P; England M; Fegan PG; Davis WA
    Diabetes Technol Ther; 2020 May; 22(5):367-373. PubMed ID: 31724878
    [No Abstract]   [Full Text] [Related]  

  • 28. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
    Dutta D; Kalra S
    J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring.
    Reddy M; Oliver N
    Diabetes Technol Ther; 2020 Mar; 22(3):235-238. PubMed ID: 31833786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
    Akturk HK; Rewers A; Garg SK
    Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NICE guidance on dapagliflozin with insulin for type 1 diabetes.
    Adler AI; Ting S; Dent R; Latimer N
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):750-751. PubMed ID: 31488391
    [No Abstract]   [Full Text] [Related]  

  • 34. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes.
    Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
    Endocr J; 2020 Oct; 67(10):1055-1062. PubMed ID: 32565500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Glycemic Metrics Measured Simultaneously by Intermittently Scanned Continuous Glucose Monitoring and Real-Time Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes.
    Nørgaard SK; Mathiesen ER; Nørgaard K; Ringholm L
    Diabetes Technol Ther; 2021 Oct; 23(10):665-672. PubMed ID: 34086494
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
    Boeder SC; Gregory JM; Giovannetti ER; Pettus JH
    Diabetes; 2022 Mar; 71(3):511-519. PubMed ID: 34857545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
    Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y
    Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.